Can Fatty Liver Cause Hypertension?

Fatty liver disease and hypertension are closely linked conditions that frequently occur together, raising the important question: can fatty liver cause hypertension? Metabolic-associated steatotic liver disease (MASLD) shares key underlying mechanisms with high blood pressure, including insulin resistance, chronic inflammation, and activation of the renin-angiotensin-aldosterone system. Understanding how these two conditions interact is essential for effective management. This article explains the evidence behind the association, the symptoms that should prompt a GP visit, and the lifestyle changes and treatments that can benefit both conditions simultaneously.

Can fatty liver cause high blood pressure?

Fatty liver disease is strongly associated with high blood pressure through insulin resistance, chronic inflammation, and increased RAAS activity, though the relationship is observational and likely bidirectional rather than definitively causal.

Fatty liver disease is strongly associated with high blood pressure, and the two conditions frequently coexist as part of the broader metabolic syndrome, though most of the evidence linking them is observational rather than definitively causal. Metabolic-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease or NAFLD) is associated with insulin resistance, chronic low-grade inflammation, and increased activity of the renin-angiotensin-aldosterone system (RAAS), all of which are recognised mechanisms that may contribute to raised blood pressure over time. Large cohort studies and meta-analyses have found that people with MASLD have a higher prevalence of hypertension compared with those without liver fat accumulation, even after accounting for shared risk factors such as obesity and type 2 diabetes, though the direction of causality remains an area of active research.

The relationship appears bidirectional. Evidence from observational studies suggests that sustained hypertension may worsen liver perfusion and promote hepatic fibrosis, meaning that each condition may accelerate the other if left unmanaged. Visceral adiposity, fat stored around the abdominal organs, is a key driver of both conditions and helps explain why they so frequently occur together.

It is worth noting that fatty liver disease does not always cause symptoms in its early stages. Assessment of MASLD in UK primary care typically involves liver function tests, calculation of the FIB-4 score (using age, AST, ALT, and platelet count), and, where indicated, further imaging or elastography, rather than blood pressure monitoring alone. If you are seeking a structured assessment, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, alongside other evidence-based options your GP may discuss with you.

What symptoms should prompt you to see a GP?

See your GP if you experience persistent fatigue, upper right abdominal pain, abdominal swelling, jaundice, or consistently raised home blood pressure readings, as these may indicate coexisting MASLD and hypertension.

You should see your GP if you experience persistent fatigue, upper right abdominal discomfort, unexplained weight gain around the abdomen, or consistently elevated home blood pressure readings, as these can all indicate that fatty liver disease and hypertension are developing together. Fatty liver disease is often described as a silent condition because many people have no symptoms at all in the early stages, and it is important to be aware that normal liver blood tests do not exclude MASLD. Management is guided by fibrosis risk assessment rather than enzyme levels alone.

Specific symptoms that warrant a GP appointment include:

• Persistent tiredness that does not improve with rest

• Dull or aching pain in the upper right side of the abdomen

• Swelling of the abdomen (ascites), which may suggest more advanced liver disease

• Yellowing of the skin or eyes (jaundice), which requires prompt medical review

• Headaches or visual disturbances that may be associated with poorly controlled blood pressure (these symptoms are non-specific and should be assessed in context)

• Swollen ankles or legs, which can reflect both cardiovascular and liver-related fluid retention

• Vomiting blood or passing black, tarry stools, which may indicate bleeding from oesophageal varices and requires urgent assessment

• Confusion or marked drowsiness, which may suggest hepatic encephalopathy in the context of advanced liver disease

If you develop a sudden severe headache, chest pain, or difficulty breathing, these may indicate a hypertensive emergency and you should call 999 immediately. Per NICE NG136, home blood pressure monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM) is used to confirm a diagnosis of hypertension; a clinic reading of 140/90 mmHg or above should prompt further assessment by your GP.^[2][3] For urgent but non-emergency concerns outside of GP hours, NHS 111 can provide guidance.

In UK primary care, assessment for suspected MASLD typically involves liver function tests and calculation of the FIB-4 score. If the FIB-4 score is indeterminate or high, your GP may arrange enhanced liver fibrosis (ELF) testing or transient elastography (FibroScan), and refer to hepatology if results suggest significant fibrosis or if features of decompensated liver disease are present, in line with NICE NG49.

What lifestyle changes and treatments can help both conditions?

Weight loss of 7 to 10 per cent, a Mediterranean-style diet, and at least 150 minutes of aerobic exercise per week are the most effective interventions for improving both fatty liver disease and blood pressure.

Weight loss is one of the most effective interventions for both fatty liver disease and hypertension. EASL-EASD-EASO clinical practice guidelines suggest that weight loss of at least 7 to 10 per cent of body weight is associated with histological improvement in liver disease, including reduction in inflammation and fibrosis, and weight loss in this range also has well-established benefits for blood pressure.^[1] NICE guidance supports a structured approach to weight management combining dietary change, increased physical activity, and behavioural support. A Mediterranean-style diet, rich in vegetables, wholegrains, legumes, oily fish, and olive oil, has evidence from clinical trials for reducing liver fat and cardiovascular risk simultaneously.^[8][9]

Regular aerobic exercise, such as brisk walking, cycling, or swimming for at least 150 minutes per week, is recommended by NHS physical activity guidelines and has been shown in systematic reviews to reduce liver fat, with some evidence that this effect is at least partly independent of weight loss. Resistance training can also improve insulin sensitivity and help lower blood pressure. Alcohol reduction or abstinence is particularly important for those with any form of liver disease, as alcohol directly worsens hepatic inflammation and raises blood pressure.

From a pharmacological perspective, your GP may consider:

• Antihypertensive medicines such as ACE inhibitors or angiotensin receptor blockers (ARBs), which are effective for blood pressure control; some preclinical and small clinical studies have suggested possible effects on hepatic fibrosis pathways, but robust clinical outcome evidence in MASLD is lacking, so the primary rationale remains blood pressure management

• Statins, which are generally considered safe in fatty liver disease according to BSG and BASL guidance, and which reduce cardiovascular risk; standard liver function test monitoring applies as per NICE lipid modification guidance^[1]

• GLP-1 receptor agonists such as semaglutide, which NICE recommends for eligible patients with obesity (NICE TA875) and which have emerging evidence for reducing liver fat in clinical trials; they are not currently licensed specifically to treat MASLD, and eligibility and prescribing decisions depend on individual clinical circumstances and the specific agent

Any medication changes should be discussed with your GP or specialist, who can weigh the benefits and risks in the context of your overall health. Self-medicating or stopping prescribed medicines without advice is not recommended.

How are fatty liver disease and hypertension linked?

Both conditions share a root in metabolic dysfunction, particularly insulin resistance and RAAS upregulation; liver fat accumulation promotes vascular inflammation and arterial stiffness, while hypertension may accelerate hepatic fibrosis.

Fatty liver disease and hypertension share a common root in metabolic dysfunction, particularly insulin resistance and chronic inflammation, which is why they so frequently coexist as components of metabolic syndrome. Metabolic syndrome is characterised by a cluster of features including central obesity, raised blood glucose, abnormal blood lipids, and high blood pressure, and MASLD is now considered both a consequence and a driver of this syndrome. According to EASL-EASD-EASO clinical practice guidelines, when the liver accumulates excess fat, it is associated with increased release of pro-inflammatory cytokines and free fatty acids into the circulation, which may impair vascular function and contribute to arterial stiffness, though the precise causal pathways in humans continue to be investigated.^[4][1]

The renin-angiotensin-aldosterone system (RAAS) is thought to play an important role in connecting the two conditions. Liver fat accumulation has been associated with upregulation of RAAS activity, which promotes sodium retention and vasoconstriction, both of which can elevate blood pressure.^[4] Conversely, observational evidence suggests that sustained hypertension may reduce hepatic blood flow and promote oxidative stress within liver tissue, potentially accelerating progression from simple steatosis (fat accumulation) to steatohepatitis (inflammation) and, over time, fibrosis.

Portal hypertension is a separate but related concept that arises specifically from advanced liver disease. As fibrosis progresses to cirrhosis, resistance to blood flow through the liver increases, raising pressure in the portal venous system. This is distinct from systemic hypertension but can coexist with it and carries its own serious complications, including oesophageal varices and ascites, as described in NHS guidance on cirrhosis.

Understanding this bidirectional association underlines why managing both conditions together, rather than in isolation, is likely to produce better long-term outcomes. Integrated care combining hepatology, cardiology, and primary care input where appropriate is supported by BSG and BASL guidance for people with coexisting MASLD and cardiovascular risk factors.^[17][1]

Frequently Asked Questions